Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Progression02:07

Tumor Progression

6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Pre-Pectoral Breast Reconstruction after Mastectomy: Current Evidence, Knowledge Gaps, and Rationale for the I-PREPARE EUBREAST-11R Trial.

Breast care (Basel, Switzerland)·2026
Same author

Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.

The Lancet. Oncology·2026
Same author

Pathological complete response and postmastectomy radiation therapy after primary systemic therapy: results from the ReSTORE study.

Breast (Edinburgh, Scotland)·2026
Same author

EBCC-15 manifesto: Removing age-related barriers to improve equity in breast cancer care.

Breast (Edinburgh, Scotland)·2026
Same author

Axillary management in patients with cN + breast cancer undergoing neoadjuvant chemotherapy: pattern of practice in Italy.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer.

CA: a cancer journal for clinicians·2026

相关实验视频

Updated: Sep 20, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

613

病理完整反应的额外危险.

Orit Kaidar-Person1, Philip Poortmans2, Icro Meattini3

  • 1Breast Cancer Radiation Therapy Unit, at Sheba Medical Center, Ramat Gan, Israel; Tel Aviv Medical School, Tel Aviv University, Israel.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
|May 29, 2025
PubMed
概括
此摘要是机器生成的。

病理完整反应 (pCR) 预测了侵袭性早期乳腺癌的结果. 本综述探讨了PCR测定挑战以及PCR后个性化放射治疗的数据需求.

关键词:
乳腺癌 乳腺癌是什么?新辅助剂是一种新辅助剂.病理完整反应的病理完整反应.主要的系统性治疗.辐射辐射辐射的辐射是什么

更多相关视频

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.0K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K

相关实验视频

Last Updated: Sep 20, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

613
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.0K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K

科学领域:

  • 在瘤学瘤学.
  • 放射疗法是一种放射治疗.
  • 乳腺癌研究研究 乳腺癌研究

背景情况:

  • 病理完整反应 (pCR) 是接受新辅助全身治疗的侵袭性早期乳腺癌患者长期结果的重要预测因素.
  • 准确评估pCR对于治疗评估和患者管理至关重要.

研究的目的:

  • 批判性地评估与确定乳腺癌病理完整反应 (pCR) 相关的方法和挑战.
  • 确定为调整乳腺癌患者实现pCR的放射治疗策略所需的基本数据.

主要方法:

  • 关于乳腺癌中pCR评估的当前文献的综述.
  • 对临床试验数据和与新辅助疗法和放射瘤学相关的指导方针的分析.
  • 讨论PCR对治疗降级和强化的影响.

主要成果:

  • 在不同研究和机构的pCR定义和病理评估中存在差异.
  • 目前的数据不足以确定所有患者子组的PCR后放射治疗决策.
  • 在某些情况下,实现pCR可能需要放缓放射治疗,但需要进一步调查.

结论:

  • 需要对PCR评估进行标准化,以提高研究结果的可比性和可靠性.
  • 需要进行进一步的研究,以确定在实现pCR后定制乳腺癌放射治疗的强有力的标准.
  • 结合pCR状态的个性化治疗策略对于优化早期乳腺癌的结果至关重要.